AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Lunai Bioworks Inc.

$2.38 -$5.39 (-69.37%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$2.44
Day Range
$2.31$2.52
Year Range
$1.21$17.52
Market Cap
10.79M
AVG Volume
860.04K
Trailing/Forward PE
-0.04/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-09-28
Primary Exchange
NASDAQUS
Net Income (USD)
-200M-150M-100M-50M02024
LNAI Net Income (USD) by year
PeriodNet Income (USD)
2024-178.01M
Operating Income (USD)
-80M-60M-40M-20M02024
LNAI Operating Income (USD) by year
PeriodOperating Income (USD)
2024-66.16M
EBITDA (USD)
-200M-150M-100M-50M02024
LNAI EBITDA (USD) by year
PeriodEBITDA (USD)
2024-177.14M
Cash Flows (USD)
-8M-6M-4M-2M02024
LNAI Cash Flows (USD) by year
PeriodCash Flows (USD)
2024-7.87M
EPS (USD)
-100-75-50-2502024
LNAI EPS (USD) by year
PeriodEPS (USD)
2024-86.39
Expenses (USD)
-5M05M10M15M20MR&DSG&ACapex2024
LNAI Expenses (USD) by year
PeriodExpenses (USD)
202418.42M
Cash & Debt (USD)
02.5M5M7.5M10MCashShort Term Debt2024
LNAI Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2024480.55K
Debt ratios
00.511.52024
LNAI Debt ratios by year
PeriodDebt ratios
20240
Return on Capital
0%250%500%750%1000%2024
LNAI Return on Capital by year
PeriodReturn on Capital
2024833.76%
Shares Outstanding
01M2M3M2024
LNAI Shares Outstanding by year
PeriodShares Outstanding
20242.08M
Book Value Per Share (USD)
-15-10-502024
LNAI Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
2024-10.25
Total Assets (USD)
02.5M5M7.5M10M2024
LNAI Total Assets (USD) by year
PeriodTotal Assets (USD)
20248.23M
Free Cash Flow Yield
-150%-100%-50%0%med -53.47%Oct 25Dec 25Jan 26Mar 26May 26Jul 26Sep 26
LNAI Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-70.73%
Sep 26-70.44%
Aug 26-71.03%
Aug 26-78.3%
Aug 26-75.83%
Aug 26-69.85%
Jul 26-86.78%
Jul 26-72.25%
Jul 26-59.7%
Jul 26-57.26%
Jul 26-52.61%
Jun 26-52.44%
Jun 26-44.54%
Jun 26-69.85%
Jun 26-68.71%
May 26-63.27%
May 26-86.23%
May 26-94.6%
May 26-73.82%
May 26-76.12%
Apr 26-78.58%
Apr 26-69.85%
Apr 26-65.61%
Apr 26-65.39%
Mar 26-59.05%
Mar 26-51.97%
Mar 26-131.67%
Mar 26-104.77%
Feb 26-86.5%
Feb 26-58.72%
Feb 26-43.54%
Feb 26-48.31%
Jan 26-41.03%
Jan 26-36.47%
Jan 26-34.6%
Jan 26-33.34%
Jan 26-32.95%
Dec 25-32.95%
Dec 25-30.48%
Dec 25-29.91%
Dec 25-25.6%
Nov 25-40.06%
Nov 25-38.12%
Nov 25-44.59%
Nov 25-50.69%
Oct 25-54.33%
Oct 25-43.77%
Oct 25-39.39%
Oct 25-41.83%
Oct 25-36.64%
Sep 25-36.36%
Sep 25-27.01%
Sep 25-23.75%
Sep 25-22.83%
Price to Sales
200300400500600med 359.54Jun 26Jul 26Jul 26Aug 26Sep 26
LNAI Price to Sales by year
PeriodPrice to Sales
Sep 26355.07
Sep 26356.56
Aug 26353.57
Aug 26320.75
Aug 26331.2
Aug 26359.54
Jul 26289.42
Jul 26347.61
Jul 26420.71
Jul 26438.61
Jul 26477.4
Jun 26478.89
Jun 26563.93
Jun 26359.54
Jun 26365.51
Lunai Bioworks Inc.
LNAI
Stockpicker

Video analysis: LNAI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: LNAI

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

prnewswire.com · 4 Sep 2026

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

prnewswire.com · 27 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

prnewswire.com · 4 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

prnewswire.com · 4 Aug 2026

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

prnewswire.com · 17 Jun 2026

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

feeds.benzinga.com · 17 Jun 2026

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Lunai Bioworks Inc. shares soared 80.88% after-hours after regaining Nasdaq compliance with minimum bid price requirements.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.